MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3201/eid2813.212123

Медицинская библиотека · Emerging infectious diseases · 2022

CDC's COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions.

Soeters Heidi M, Doshi Reena H, Fleming Monica, Adegoke Oluwasegun Joel, Ajene Uzoamaka, Aksnes Brooke Noel, Bennett Sarah, Blau Erin F, Carlton Julie Garon, Clements Sara, Conklin Laura, Dahlke Melissa, Duca Lindsey M, Feldstein Leora R, Gidudu Jane F, Grant Gavin, Hercules Margaret, Igboh Ledor S, Ishizumi Atsuyoshi, Jacenko Sara, Kerr Yinka, Konne Nuadum M, Kulkarni Shibani, Kumar Archana, Lafond Kathryn E, Lam Eugene, Longley Ashley T, McCarron Margaret, Namageyo-Funa Apophia, Ortiz Nancy, Patel Jaymin C, Perry Robert T, Prybylski Dimitri, Reddi Prianca, Salman Omar, Sciarratta Courtney N, Shragai Talya, Siddula Akshita, Sikare Ester, Tchoualeu Dieula Delissaint, Traicoff Denise, Tuttle Alexandra, Victory Kerton R, Wallace Aaron, Ward Kirsten, Wong Man Kai Alyssa, Zhou Weigong, Schluter W William, Fitter David L, Mounts Anthony, Bresee Joseph S, Hyde Terri B

СтатьяОбзорПеревод в очереди

Аннотация

The US Centers for Disease Control and Prevention (CDC) supports international partners in introducing vaccines, including those against SARS-CoV-2 virus. CDC contributes to the development of global technical tools, guidance, and policy for COVID-19 vaccination and has established its COVID-19 International Vaccine Implementation and Evaluation (CIVIE) program. CIVIE supports ministries of health and their partner organizations in developing or strengthening their national capacities for the planning, implementation, and evaluation of COVID-19 vaccination programs. CIVIE's 7 priority areas for country-specific technical assistance are vaccine policy development, program planning, vaccine confidence and demand, data management and use, workforce development, vaccine safety, and evaluation. We discuss CDC's work on global COVID-19 vaccine implementation, including priorities, challenges, opportunities, and applicable lessons learned from prior experiences with Ebola, influenza, and meningococcal serogroup A conjugate vaccine introductions.

Для цитирования: Soeters Heidi M, Doshi Reena H, Fleming Monica, Adegoke Oluwasegun Joel, Ajene Uzoamaka, Aksnes Brooke Noel, Bennett Sarah, Blau Erin F, Carlton Julie Garon, Clements Sara, Conklin Laura, Dahlke Melissa, Duca Lindsey M, Feldstein Leora R, Gidudu Jane F, Grant Gavin, Hercules Margaret, Igboh Ledor S, Ishizumi Atsuyoshi, Jacenko Sara, Kerr Yinka, Konne Nuadum M, Kulkarni Shibani, Kumar Archana, Lafond Kathryn E, Lam Eugene, Longley Ashley T, McCarron Margaret, Namageyo-Funa Apophia, Ortiz Nancy, Patel Jaymin C, Perry Robert T, Prybylski Dimitri, Reddi Prianca, Salman Omar, Sciarratta Courtney N, Shragai Talya, Siddula Akshita, Sikare Ester, Tchoualeu Dieula Delissaint, Traicoff Denise, Tuttle Alexandra, Victory Kerton R, Wallace Aaron, Ward Kirsten, Wong Man Kai Alyssa, Zhou Weigong, Schluter W William, Fitter David L, Mounts Anthony, Bresee Joseph S, Hyde Terri B. CDC's COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions.. Emerging infectious diseases. 2022. DOI: 10.3201/eid2813.212123.

Предметные рубрики MeSH

United StatesHumansCOVID-19 VaccinesSARS-CoV-2COVID-19Influenza VaccinesCenters for Disease Control and Prevention, U.S.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.